Cathepsin L1 Antibodies

Cathepsin L1 (CTSL)

Important for the overall degradation of proteins in lysosomes. .

Gene Information

Human
Gene Name:	CTSL
Uniprot:	P07711
Entrez:	1514

Family

Belongs to:
peptidase C1 family

Alternative Names

Cathepsin L; cathepsin L1; CATL; CTSL; CTSL1; CTSLEC 3.4.22.15; EC 3.4.22; FLJ31037; Major excreted protein; MEP

Molecular Weight

Mass (kDA):
37.564 kDA

Genomic Context

Human
Location:	9q21.33
Sequence:	9; NC_000009.12 (87725437..87731469)

Subcellular Localizations

Lysosome. Apical cell membrane; Peripheral membrane protein; Extracellular side. Localizes to the apical membrane of thyroid epithelial cells.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Cell Invasion
• Neoplasm Metastasis
• Malignant Paraganglionic Neoplasm
• Neoplasm Invasiveness
• Arthritis
• Malignant Squamous Cell Neoplasm
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Rheumatoid Arthritis
• Adenocarcinoma

• Inflammation
• Tumor Angiogenesis
• Lung Neoplasms
• Tumor Progression
• Melanoma
• Cell Transformation, Neoplastic
• Colorectal Neoplasms

Interacting Proteins

• SGTA

Pathways

• Proteolysis
• Secretion
• Localization
• Pathogenesis
• Bone Resorption
• Angiogenesis
• Cell Death
• Translation
• Transport
• Autophagy
• Cell Proliferation
• Glycosylation
• Cell Adhesion

• Tissue Remodeling
• Membrane Fusion
• Antigen Processing And Presentation
• Reverse Transcription
• Ovulation
• Immune Response
• Phagocytosis

PTMs

• Cleavage
• Phosphorylation
• Glycosylation
• Reduction
• Methylation

• Carboxylation
• Oxidation
• Nitration
• Biotinylation
• Phosphorothioation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CTSL

The Boster Bio - Best Uses Of The CTSL Marker

Boster Bio is probably something you've heard about. You might be curious how to optimize your experiments, now that you have seen it in operation. The good news is that the Boster Bio has a wealth of options for optimization. For more information, please read the following. We'll cover the cost, availability, and treatment options. We will also discuss the risks involved in using this new tool.

Treatment options

NSCLC's CTSL marker could be a therapeutic target. This lysosomal enzyme is upregulated in many malignancies, including breast and lung cancer. CTSL inhibition enhances drug targets, stabilizes tumour microenvironment, and reduces tumor growth. It is not known how CTSL contributes specifically to NSCLC. The role CTSL has in NSCLC remains unclear.

Several cancer treatments are available for patients with high levels of CTSL in their tumors. CTSL has been shown not to allow SARS-CoV-2 into the body, which is a major cause of SARS. Inhibition of CTSL inhibits tumor growth by 76%. This suggests that targeting CTSL might be an effective treatment to the SARS virus-CoV-2. CTSL is also linked to glioblastomamultiforme.

EMT can be caused by CTSL overexpression in A549 cancer cell lines. EMT-associated proteins such as cytokeratin-18 are enhanced by blocking CTSL. CTSL also promotes EMT through transcription factors involved in EMT. CTSL silencing can reduce CTSL expression for A549 tumors. In addition, CTSL overexpression reduces sensitivity to paclitaxel.

Mut-p53 inhibits CTSL transcription in a lung cancer cell strain with different mutation spots. IR also increased CTSL expression and the tumor cells displayed enhanced EMT activity. Similarly, mut-p53 (R273H) could bind to CTSL and inhibit EMT. KGP94, which inhibits CTSL, is found in lung cancer cells. This indicates that CTSL can regulate EMT. CTSL is therefore a valuable therapeutic target for lung carcinoma.

Patients with CTSL positive cancer must be treated to address the cause. Anti-KGP94 inhibitors can be used to target CTSL and may prevent tumor growth. CTSL-targeted medications may be useful in treating metastatic tumors, as well as inflammatory disorders and autoimmune conditions. CTSL is a potential therapeutic target. Currently, however, there are no approved CTSL inhibitors.

Molecular testing for CTSL-positive lung cancer cells will provide a better understanding of its role in the disease. Western blotting is a method that can detect CTSL and other potential therapeutic targets. Mutant p53 may increase CTSL expression in lung carcinoma cells. Western blotting is also able to identify potential roles for CTSL/mut53 in cancer. It is possible to predict the clinical outcome of these therapies.

Costs

The CTSL Marker may be used to detect plaque inflammation and vulnerability. It is unknown how it contributes, however, to plaque instability and necrotic core growth. The CTSL Marker (Certificate of Transparent Lightness) is one of many emerging technologies for the electrical sector. The market for CTs continues to grow rapidly. It has the potential to reduce both costs and energy consumption. It is necessary to further study its role.

Available

The availability of the CTSL Marker in serum can help in the diagnosis of ovarian cancer. This protein is increased in malignancies. The level of the CTSL Marker in serum is correlated with the severity of the malignancy. It has been implicated both in tumor invasion, metastasis, and other aspects of cancer. Although CTSL gene expression is not widespread, it may be useful for biomarkers of ovarian tumors. Here's a quick explanation of this marker.

CTSL is a cysteine protease that plays a key role in the degradation and repair of lysosomal cells. CTSL is expressed in cancer cells and secreted to the extracellular matrix. CTSL preferentially cuts the hydrophobic, and aromatic residues within peptides at position P2 and 3 because of an acidic environment caused locally by anaerobic Glylysis. CTSL cleaves peptides, which increases invasion and metastasis in cancer cells.